A Phase 3 interventional study of Tedisamil sesquifumarate in Atrial Fibrillation and Atrial Flutter, sponsored by Solvay Pharmaceuticals. Completed at 26 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.
Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.
3,957 studies on the registry are indexed under Atrial Fibrillation; 933 are open to participants now.
Browse Atrial Fibrillation studies →Solvay Pharmaceuticals is the lead sponsor of 86 studies on the registry; none are open to participants now.
First submitted before Solvay Pharmaceuticals became part of Abbott.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The record gives a start of Oct 2004, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedisamil sesquifumarate